Evaluating kidney and blood pressure outcomes in childhood cancer survivors
KIdney aNd blooD prESsure ouTcomes in Childhood Cancer Survivors (CCS): Prospective Study
This study is trying to see how common kidney problems and high blood pressure are in childhood cancer survivors a few years after their treatment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 500 (estimated) |
| Ages | N/A to 19 Years |
| Sex | All |
| Sponsor | The Hospital for Sick Children Academic / other |
| Drugs / interventions | radiation, methotrexate |
| Locations | 1 site (Toronto, Ontario) |
| Trial ID | NCT06153147 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on childhood cancer survivors (CCS) who are at increased risk for chronic kidney disease (CKD) and hypertension (HTN) due to their cancer treatments. It aims to determine the prevalence of CKD and HTN at 3 and 5 years post-therapy, while also assessing the progression of kidney function and blood pressure over this period. The study will involve 500 CCS who received high-risk therapies and will analyze the relationship between acute kidney injury during treatment and subsequent cardiovascular risks. The findings will help refine guidelines for monitoring and managing kidney and blood pressure health in CCS.
Who should consider this trial
Good fit: Ideal candidates are childhood cancer survivors who are 3 years post-therapy and received high-risk cancer treatments.
Not a fit: Patients with pre-existing severe chronic kidney disease or those over 19 years old at the time of therapy completion will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved guidelines for monitoring and treating kidney and blood pressure issues in childhood cancer survivors, enhancing their long-term health outcomes.
How similar studies have performed: While there is existing evidence on CKD and HTN in select patients, this study aims to fill significant knowledge gaps, making it a novel approach in this specific population.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * 3 years ± 6 months after therapy for first cancer * Received high-risk therapy for first cancer, as defined by the Canadian Oncology Group (COG) as alkylating agents; platinums; abdominal or total body radiation; high dose methotrexate; stem cell transplant; nephrectomy; or other therapy which may be known to possibly cause late kidney and/or BP effects. Exclusion Criteria: * Pre-cancer severe CKD and/or previous kidney transplant * \>19 years old at 3 years after cancer therapy completion
Where this trial is running
Toronto, Ontario
- The Hospital For Sick Children — Toronto, Ontario, Canada (Recruiting)
Study contacts
- Study coordinator: Michael Zappitelli, MD
- Email: michael.zappitelli@sickkids.ca
- Phone: 4168137605
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.